JCPSLP Vol 17 No 2 2015_web

References de Groen, P. C. Lubbe, D. F., Hirsch, L. J., Daifotis, A., Stephenson, W., Freedholm, D., & Wang, K. K., (1996). Esophagitis associated with the use of alendronate. New England Journal of Medicine , 335 (14), 1016–1021. Gallagher, L., & Naidoo, P. (2009). Prescription drugs and their effects on swallowing. Dysphagia , 24 (2), 159–66. Gurwitz, J. H., Field, T. S., Harrold, L. R., & Rothschild, J. (2003). Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA , 289 (9), 1107–1116. Marquis, J., Schneider, M., Payot, V., Cordonier, A., Bugon, O., Hersberger, K.E., & Arnet, I. (2013). Swallowing difficulties with oral drugs among polypharmacy patients attending community pharmacies. International Journal of Clinical Pharmacy , 35 , 1130–1136. Nunn, T., & Williams, J. (2005). Formulation of medicines for children. British Journal of Clinical Pharmacology , 59 (6) 674–676.

Scheile, J. T., Quinzler, R., Klimm, H., Pruszydlo, M. G., & Hefeli, W. E. (2013). Difficulties swallowing solid oral dosage forms in a general practice population: Prevalence, causes, and relationship to dosage forms. European Journal of Clinical Pharmacology , 69 , 937–948. Singh, J., Philip, A.K., & Pathak, K. (2008). Optimization studies on design and evaluation of orodispersible pediatric formulation of indomethacin. AAPS PharmSciTech 9 (1), 60–66. Emily Davis is the manager of speech pathology at the Bathurst Health Service in New South Wales, and works primarily with acute and rehabilitation patients with swallowing and communication difficulties. Derek Kay is the director of pharmacy at the Bathurst Health Service.

Correspondence to: Emily Davis Bathurst Health Service email: emily.davis@health.nsw.gov.au

93

JCPSLP Volume 17, Number 2 2015

www.speechpathologyaustralia.org.au